NOW APPROVED 
in 1L unresectable HCC

THE STRENGTH OF SUPERIOR SURVIVAL  

For over a decade, systemic therapy
for 1L HCC has shown poor survival
benefit and decreased patient QoL.
TECENTRIQ + bevacizumab, the first and only cancer immunotherapy combination in 1L unresectable HCC is revolutionising the treatment paradigm and bringing new hope to patients. 1-4

HCC IS AN AGGRESSIVE CANCER WITH
LIMITED SYSTEMIC TREATMENT OPTIONS5

HCC is the 4th leading cause of cancer deaths worldwide6;
less than half of patients with unresectable HCC are still alive
1 year after diagnosis.7

TECENTRIQ + BEVACIZUMAB,
THE FIRST AND ONLY
CANCER IMMUNOTHERAPY
COMBINATION IN 1L
UNRESECTABLE HCC4

A young female healthcare practitioner smiles kindly at a male patient.

THE DEVELOPMENT OF TECENTRIQ IS BASED ON AN
EXTENSIVE CLINICAL PROGRAMME ADDRESSING KEY UNMET
MEDICAL NEEDS ACROSS DIFFERENT TUMOUR TYPES.

 

TECENTRIQ INDICATIONS

TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.1

IMBRAVE150: FIRST SUCCESSFUL, PHASE III TRIAL OF
CANCER IMMUNOTHERAPY COMBINATION VS SORAFENIB IN
1L UNRESECTABLE HCC4

 

A global, open-label, Phase III, randomized trial in patients with previously untreated unresectable  HCC 4

  • ddd

    UNPRECEDENTED SURVIVAL IN 1L UNRESECTABLE HCC4

    Significant reduced risk of death demonstrated with TECENTRIQ + bevacizumab vs sorafenib4

    1L=first line; CI=confidence interval; HR=hazard ratio; NE=not estimable; OS=overall survival.

     

    Median OS was a coprimary endpoint

  • dddd

    SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN 1L UNRESECTABLE HCC

    TECENTRIQ + bevacizumab demonstrated a 41% reduction in disease progression or death vs sorafenib1

    1L=first line; CI=confidence interval; HR=hazard ratio; PFS=progression-free survival; RECIST=Response Evaluation Criteria In Solid Tumors.

     

    Median PFS as assessed by IRF per RECIST v1.1 was a coprimary endpoint

  • dddd

    MORE THAN DOUBLE THE OVERALL RESPONSE RATE VS SORAFENIB
    IN 1L UNRESECTABLE HCC

    TECENTRIQ + bevacizumab reduced tumour burden vs sorafenib and have demonstrated complete responses in 7% of
    patients compared to 0% with sorafenib1

    ORR as assessed by HCC mRECIST was 33% with TECENTRIQ + bevacizumab (n=112/336; 95% CI, 28, 39) vs 13% with sorafenib (n=21/165; 95% CI, 8, 19)

    – CR: 11% vs 1.8%               

    – PR: 22% vs 11%

     

    At the time of analysis, median DoR was not yet reached with TECENTRIQ + bevacizumab (95% CI, NE, NE; range: 1.3+, 13.4+ mo) vs 6.3 months with sorafenib 

    (95% CI, 4.7, NE; range: 1.4+, 9.1+ mo)*

     

    1L=first line; CI=confidence interval; CR=complete response; DoR=duration of response; HCC mRECIST=hepatocellular carcinoma modified Response Evaluation Criteria In Solid Tumors; IRF=independent review facility; ORR=overall response rate; PR=partial response; RECIST=Response Evaluation Criteria In Solid Tumors.

    *Assessed by IRF per RECIST v1.1. 

    †Confirmed responses.

TECENTRIQ + bevacizumab:
SUPERIOR SURVIVAL AND
ESTABLISHED SAFETY IN 1L UNRESECTABLE HCC 

What this means for patients with HCC

  • View video transcript

    Mr. Yan:

    None of my family or friends would believe it, it was a fast-growing HCC.  The day before I experienced the pain, I went skiing with friends in Chongli Ski Resort, we also had dinner and drinks together. 

    Two days later when I came back to Beijing, I was diagnosed. The news was completely unexpected.

     

    Dr. Toh Han Chong:

    HCC is usually diagnosed late because early cancers don't have any symptoms. If untreated, it's actually a very rapidly progressive disease.  

     

    Mr. Yan:

    In less than a week, it grew from 9cm to 16cm and finally when it was removed,it was nearly 17cm.

    I was told to go home and make the most of my last three months [of] life. “Visit the places on your bucket list, enjoy the foods you love as much as possible, do whatever you want.”  I couldn’t accept it at the time, and my wife couldn’t accept it, my son was only 2 years old. 

     

    Dr. Toh Han Chong:

    In terms of the management of HCC, just to use a personal experience, when I was a young doctor the management of advanced HCC was very dismal, the median survival was just a couple of months.

    Today the world has changed phenomenally. Not only are there many drugs, there are drugs that can actually control this disease for a long period of time. 

     

    Mr. Yan:

    My greatest hope is to continue being with my family, with my wife and my son. 

    You know that’s my greatest hope.

    View video transcript

  • View video transcript

    I started taking physicals every year, probably about 30 years ago. And then in the early 90s, I was evaluated one year during my physical that I had hepatitis C. But I didn’t really get rid of it until probably the last five years. In 2010, I was diagnosed with prostate cancer. It took a few years for it to end up in remission.

     

    And only after they tried to treat the cirrhosis of the liver, afterwards I found out I had liver cancer. And only after my diagnosis of liver cancer, was I educated and told that hepatitis C was a risk factor for liver cancer. It knocked me for a loop, because I didn’t realise that my health situation is moving downhill in a sense. I go from prostate cancer to cirrhosis of the liver and then I'm hearing about liver cancer.

     

    I was sad. I was disappointed. It's like, why do I have to deal with this? But my attitude was, I'm going to hang in there. I'm willing to put forth the effort. I didn't know what it was going to take, but I was willing. And I'm glad I went along with it.

     

    I met my wife in late 2016. I think it was right around September. We were at a gathering and we didn’t know each other, but at some point during the gathering I went up and introduced myself. It was dry up until before I met her, because of the medical issues that was going on with me.

     

    My mother passed and she was probably my biggest fan. But in 2016, my best buddy passed away. So that left a void. Just at the moment that I wanted to talk, she was there. And then we got married in September 2018. I was able to look at my medical situation with two set of eyes.

     

    So you got two people asking questions instead of one. And that was real helpful to me. And then you have to do your part by being involved in the treatment. Because as long as I'm feeling like we're doing something versus doing nothing, why not do it?

     

    I may not be out of the woods, but I can see the light at the end of the tunnel. You always look forward, seeing the sun come up, and taking your next breath. That's part of the deal, whether you acknowledge it or not. I might be here a little while longer. How about that? Yes, I like that one. I guess most people would. 

    View video transcript

Resources

Curious to see more resources and download material?

Connecting YOU WITH YOUR PATIENTS

CONNECTING YOU WITH YOUR PATIENTS

At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.

Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC). 

TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). Please see the specific indications for more information.

Connecting TECENTRIQ and COMBINATIONS

CONNECTING TECENTRIQ AND COMBINATIONS

TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to explore new combinations for better patient outcomes (ref. SmPC).

In many difficult-to-treat tumour types with a high unmet need, including metastatic urothelial carcinoma, triple negative breast cancer and lung cancer (non-small cell lung cancer and small cell lung cancer), TECENTRIQ has shown significant improvements in progression-free and/or overall survival (ref. SmPC). Importantly, treatment can be tailored (i.e., in combination with the standard of care, or different dosing schedules) according to the type of cancer and the patient’s individual needs (ref. SmPC).
Read SmPC for more details

The multiple indications of TECENTRIQ (ref. SmPC)
provide a wealth of data to inform treatment decision-making and deliver valuable reassurance when considering the needs of your patients with cancer. Please see the specific indications for more information.

Connecting PATIENTS TO THEIR LOVED ONES

CONNECTING PATIENTS TO THEIR LOVED ONES

TECENTRIQ treatment offers the potential to improve treatment outcomes and maintain patient quality of life in your difficult to treat cancer patients, so they can hopefully spend more time with their loved ones.

TECENTRIQ is approved in metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer and triple negative breast cancer (ref. SmPC).

  • References & Notes

    References & Notes

    1. TECENTRIQ SmPC; CHMP post-authorisation summary of positive opinion for Tecentriq (II-39) avalable from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/tecentriq-2 First published: 18/09/2020 EMA/CHMP/488242/2020

    2 . Li D, et al. Cancers. 2019;11:841.

    3. Kudo M, Finn R, Qin S, et al. Lancet. 2018;391:1163–1173.

    4. Finn R, et al. N Engl J Med 2020; 382:1894-1905

    5. Llovet JM et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

    6. World Health Organisation: Globocan 2018 – Liver cancer factsheet. [Internet; cited 2020 September] Available from:  http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf 

    7. Giannini EG et al. Prognosis of Untreated Hepatocellular Carcinoma. Hepatology. 2015;61 (1):184-190.